Prestige Consumer Healthcare (NYSE:PBH) Upgraded at StockNews.com

StockNews.com upgraded shares of Prestige Consumer Healthcare (NYSE:PBH) from a hold rating to a buy rating in a research report released on Tuesday morning.

Other analysts have also recently issued research reports about the company. Oppenheimer raised their price objective on Prestige Consumer Healthcare from $87.00 to $93.00 and gave the stock an “outperform” rating in a research report on Thursday, February 13th. Canaccord Genuity Group lifted their price target on Prestige Consumer Healthcare from $93.00 to $100.00 and gave the stock a “buy” rating in a research report on Friday, February 7th. Raymond James raised Prestige Consumer Healthcare to a “moderate buy” rating in a research report on Thursday, December 19th. DA Davidson lifted their price target on Prestige Consumer Healthcare from $95.00 to $104.00 and gave the stock a “buy” rating in a research report on Friday, February 7th. Finally, Sidoti cut Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price target for the company. in a research report on Monday, December 9th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $92.60.

Prestige Consumer Healthcare Stock Down 1.0 %

Prestige Consumer Healthcare stock opened at $84.01 on Tuesday. The company has a debt-to-equity ratio of 0.56, a current ratio of 3.68 and a quick ratio of 2.20. The stock has a market capitalization of $4.16 billion, a price-to-earnings ratio of 19.67, a PEG ratio of 2.69 and a beta of 0.46. Prestige Consumer Healthcare has a 1-year low of $62.35 and a 1-year high of $90.04. The business has a fifty day moving average price of $81.87 and a 200-day moving average price of $78.45.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings data on Thursday, February 6th. The company reported $1.22 earnings per share for the quarter, topping analysts’ consensus estimates of $1.18 by $0.04. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. Equities research analysts forecast that Prestige Consumer Healthcare will post 4.5 EPS for the current fiscal year.

Insider Buying and Selling at Prestige Consumer Healthcare

In other Prestige Consumer Healthcare news, SVP Mary Beth Fritz sold 1,678 shares of Prestige Consumer Healthcare stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $90.00, for a total transaction of $151,020.00. Following the completion of the transaction, the senior vice president now owns 17,157 shares in the company, valued at approximately $1,544,130. This trade represents a 8.91 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 1.60% of the company’s stock.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Institutional investors and hedge funds have recently modified their holdings of the business. JPMorgan Chase & Co. increased its stake in shares of Prestige Consumer Healthcare by 3.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 272,255 shares of the company’s stock valued at $19,630,000 after purchasing an additional 8,533 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Prestige Consumer Healthcare by 4.0% in the 3rd quarter. Geode Capital Management LLC now owns 1,326,794 shares of the company’s stock valued at $95,678,000 after purchasing an additional 50,961 shares in the last quarter. Avior Wealth Management LLC increased its stake in shares of Prestige Consumer Healthcare by 1,570.7% in the 4th quarter. Avior Wealth Management LLC now owns 8,554 shares of the company’s stock valued at $668,000 after purchasing an additional 8,042 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in shares of Prestige Consumer Healthcare by 5.6% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 636,020 shares of the company’s stock valued at $49,667,000 after purchasing an additional 33,844 shares in the last quarter. Finally, Barclays PLC increased its stake in shares of Prestige Consumer Healthcare by 346.3% in the 3rd quarter. Barclays PLC now owns 92,444 shares of the company’s stock valued at $6,665,000 after purchasing an additional 71,730 shares in the last quarter. Hedge funds and other institutional investors own 99.95% of the company’s stock.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.